Unveiling the potential capacity of the RANKL/RANK axis to modulate the tumor immune microenvironment opens the door to the development of pharmacological inhibitors of RANKL as a potential therapy for bone disease in cancer patients. This evidence concerns the gene TNFRSF11A and neoplasm.